Lanostane Triterpenes in Medicinal Mushrooms

Beta-Glucans and Immune Function

4 rings: the tetracyclic scaffold shared by ganoderic acids, zhankuic acids, and inotodiol

Ganoderic acids (reishi), zhankuic acids (Antrodia), pachymic acids (Fu Ling), and inotodiol (Chaga) are all derived from the same tetracyclic lanosterol backbone. The lanostane scaffold is what connects these seemingly unrelated compounds from different mushroom genera into a single chemical family.

Galappaththi et al., Biomolecules, 2022

495+

lanostane-type triterpenoids identified across Ganoderma species, all variations on the same four-ring C30 lanosterol backbone (Galappaththi et al., 2022)

HMG-CoA

reductase (the enzyme that makes cholesterol) is structurally similar to the lanostane compounds, which is why lanostane triterpenes can competitively inhibit it

Absorption difference

lanostane triterpenes absorb differently from ergostane triterpenes in intestinal cell models, suggesting structural class affects bioavailability (Wang et al., 2015)

Galappaththi et al., Biomolecules, 2022

View as image ↗

When you read about ganoderic acids in reishi, zhankuic acids in Antrodia, pachymic acid in Fu Ling, and inotodiol in Chaga, you are reading about the same chemical family. All of these compounds share a tetracyclic ring system derived from lanosterol, making them all lanostane-type triterpenes despite having different names and coming from different mushroom genera.

This unifying structural fact is almost never stated in consumer content about medicinal mushrooms. The compounds get discussed species by species without the connecting chemical thread that makes sense of why mushrooms as biologically diverse as reishi, Antrodia, Poria cocos, and Chaga have such similar pharmacological properties: anti-inflammatory, HMG-CoA reductase inhibition, liver protection, and immune modulation. They are working through structurally related compounds on structurally similar molecular targets.

Galappaththi and colleagues' 2022 review identified over 495 lanostane-type triterpenoids across Ganoderma species alone, all variations on the same four-ring C30 lanosterol backbone.^[1]

Key Takeaways

Lanostane triterpenes are C30 triterpenoids built on a tetracyclic ring system derived from lanosterol; they are distinguished from ergostane triterpenes by their ring structure and from sterols by their C30 carbon count
Ganoderic acids (reishi/Ganoderma), zhankuic acids (Antrodia), pachymic acid and poricoic acids (Poria/Fu Ling), and inotodiol (Chaga/Inonotus) all share the lanostane tetracyclic scaffold: different names, same structural family
The HMG-CoA reductase inhibition mechanism documented for reishi's ganoderic acids reflects the structural similarity between lanostane C30 compounds and cholesterol precursors; the lanostane ring system resembles cholesterol's early biosynthesis intermediates (Rahman et al., 2018)
Over 495 lanostane-type triterpenoids have been identified in Ganoderma species, all variations of the same tetracyclic backbone with different functional group attachments (Galappaththi et al., 2022)
Zhankuic acids from Antrodia camphorata showed anti-inflammatory activity by inhibiting NF-kB and cyclooxygenase pathways, consistent with lanostane class pharmacology documented in Ganoderma (Shen et al., 2004)
Lanostane and ergostane triterpenes from Antrodia show different intestinal absorption rates in Caco-2 cell models, suggesting structural subclass affects bioavailability (Wang et al., 2015)

What a Lanostane Triterpene Is

To understand the lanostane family, start with the biosynthetic origin. All triterpenes are built from two-carbon isoprene units assembled into a 30-carbon chain (hence C30) via the mevalonate pathway. At the 30-carbon stage, the compound is squalene. Squalene cyclizes into different tetracyclic or pentacyclic scaffolds depending on which cyclase enzyme acts on it.

The lanosterol cyclase produces lanosterol, a four-ring (tetracyclic) compound that is also the first step in cholesterol biosynthesis in animals. Fungi use a version of the same pathway, producing lanosterol and then diverting it into a vast array of lanostane-type metabolites through subsequent modifications: oxidations, reductions, methylations, and lactonizations that produce the hundreds of different ganoderic acids, zhankuic acids, and related compounds.

The four-ring tetracyclic system (three six-membered rings and one five-membered ring, labeled A/B/C/D) is the shared structural core. What differs between specific lanostane compounds is what groups are attached to the ring system and at which positions, and what oxidation state the various carbons are in.

Galappaththi and colleagues' comprehensive 2022 review classified Ganoderma lanostanoids into structural subtypes based on the C-8,9 bond position: 8,9-ene types (with a double bond between carbons 8 and 9), 8,9-dihydro types (the double bond saturated), and 8,9-epoxy types (an oxygen bridge).^[1] These structural variations correlate with different biological activities.

The Reishi Library: 495+ Ganoderic Acids

Reishi (Ganoderma lucidum) produces the most studied and most numerous collection of lanostane triterpenes known in any mushroom species. The 495+ compounds identified by Galappaththi's review represent a remarkable degree of structural diversity from a single organism's metabolic variation on the lanostane scaffold.

Ganoderic Acid A is one of the most studied individual compounds in this library. Sui and colleagues published a 2025 comprehensive review specifically on Ganoderic Acid A, covering its pharmacological effects across anti-tumor, anti-inflammatory, antioxidant, neuroprotective, and immune-modulating properties.^[3] The range of activities documented for a single ganoderic acid compound illustrates how structurally diverse the full 495-compound library must be in its biological effects.

Wang and colleagues' 2024 five-year research progress review on ganoderic acids documented the continuing expansion of the library and the advancing understanding of structure-activity relationships: which specific features of the lanostane scaffold are responsible for which biological effects.^[2]

The Cholesterol Connection: Why Lanostane Compounds Inhibit HMG-CoA Reductase

One of the most pharmacologically important properties of certain lanostane triterpenes is their ability to inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis that is also the target of statin drugs.

The structural explanation is direct: lanosterol is an intermediate in the cholesterol biosynthesis pathway. Lanostane compounds structurally resemble cholesterol precursors that HMG-CoA reductase's downstream products lead toward. Compounds that resemble a biosynthetic intermediate can competitively inhibit the enzyme that helps produce it, because the enzyme's active site recognizes the structural features shared between the natural substrate and the inhibitor.

Rahman and colleagues (2018) evaluated the hypocholesterolemic effects of Ganoderma lucidum and documented HMG-CoA reductase inhibition as a key mechanism.^[6] This mechanism is not unique to reishi: any lanostane compound with sufficient structural similarity to the HMG-CoA reductase substrate region has potential cholesterol-lowering activity. This is why multiple lanostane-containing mushrooms (reishi, Antrodia) have documented cholesterol-relevant pharmacology.

Antrodia: Zhankuic Acids as the Taiwan Parallel

Antrodia camphorata (now classified as Antrodia cinnamomea), a medicinal mushroom from Taiwan's sacred camphor trees, produces its own library of lanostane triterpenes including zhankuic acids and antcins. These share the tetracyclic lanostane backbone but have different functional group patterns than the ganoderic acids.

Shen and colleagues (2004) isolated zhankuic acids from Antrodia camphorata fruiting bodies and documented anti-inflammatory activity through inhibition of NF-kB signaling and cyclooxygenase pathways.^[5] These are the same pathways that ganoderic acids from reishi affect. The pharmacological convergence reflects the structural convergence: both compound classes are variations on the lanostane scaffold, and the scaffold determines which molecular targets are accessible.

The structural distinction between reishi's and Antrodia's lanostanoids lies in the specific oxidation pattern and functional group arrangement; reishi emphasizes carboxylic acid groups on the side chain (hence "ganoderic acids"), while Antrodia produces aldehyde-rich variants and different hydroxylation patterns.

Chaga: Inotodiol and the Lanostane Connection

Chaga mushroom (Inonotus obliquus) is less structurally similar to reishi than Antrodia but still contains lanostane-type triterpenoids including inotodiol and lanosterol itself.

Kim and colleagues (2020) characterized the triterpenoid composition of Inonotus obliquus and identified inotodiol as one of the key compounds with anti-proliferative activity against cancer cell lines.^[7] Inotodiol is a lanostane-class compound with a specific oxidation pattern different from ganoderic acids but belonging to the same tetracyclic structural family.

Ern and colleagues' 2024 review of Chaga's therapeutic properties discussed inotodiol among the key active compounds contributing to the mushroom's documented biological activities.^[8]

The presence of lanosterol itself in Chaga (in addition to inotodiol) is notable: lanosterol is the direct precursor that all lanostane triterpenes are derived from, and Chaga contains the parent compound alongside its metabolized derivatives.

Bioavailability: Do Lanostane Triterpenes Absorb?

An important practical question for any mushroom compound is whether it is absorbed after oral consumption. Triterpenes are lipid-soluble compounds that require dietary fat for optimal absorption.

Wang and colleagues (2015) used a Caco-2 cell model (an intestinal cell culture model for studying absorption) to compare lanostane and ergostane triterpenes from Antrodia cinnamomea.^[4] The lanostane and ergostane subclasses showed different absorption rates, with structural features determining which compounds are taken up more efficiently by intestinal cells.

This finding has practical implications: the bioavailability of specific lanostane compounds varies based on their structural features, not just the total lanostane triterpene content. Consuming mushroom products containing lanostane triterpenes with dietary fat (an oil-based preparation, or taking supplements with a meal containing fat) improves absorption for lipid-soluble compounds generally.

Why This Chemical Framework Matters

Understanding that ganoderic acids, zhankuic acids, poricoic acids, and inotodiol are all lanostane compounds does more than satisfy chemical curiosity. It explains why:

Reishi, Antrodia, Fu Ling, and Chaga share pharmacological properties (NF-kB inhibition, HMG-CoA reductase activity, anti-inflammatory effects) despite being different genera
Research on ganoderic acids can inform hypotheses about related lanostane compounds in other species
The structural diversity within each species' lanostane library translates to a diversity of biological targets that no single compound can represent

When supplement labels specify "triterpenoids" or "ganoderic acids" without further structural detail, they are gesturing at a specific chemical family without communicating which members of that family the product contains or in what concentrations.

The Bottom Line

Lanostane triterpenes are C30 tetracyclic compounds derived from lanosterol that form the structural backbone of ganoderic acids (Ganoderma/reishi), zhankuic acids (Antrodia), pachymic and poricoic acids (Poria/Fu Ling), and inotodiol (Chaga/Inonotus). Over 495 lanostane-type triterpenoids have been characterized from Ganoderma species alone (Galappaththi et al., 2022). The shared structural feature explains why these compounds across different mushroom genera show similar pharmacology including HMG-CoA reductase inhibition and NF-kB pathway suppression. Lanostane and ergostane triterpenes have different intestinal absorption profiles (Wang et al., 2015), and fat-soluble lanostane compounds absorb better with dietary fat.

Frequently Asked Questions

A lanostane triterpene is a C30 triterpenoid built on the tetracyclic ring system of lanosterol: three six-membered rings and one five-membered ring arranged in a characteristic four-ring (A/B/C/D) pattern. Lanosterol is itself the first tetracyclic intermediate in cholesterol biosynthesis. Fungi produce hundreds of lanostane-type compounds by modifying the lanosterol backbone with oxidations, reductions, and other chemical transformations. All ganoderic acids, zhankuic acids, pachymic acids, and inotodiol share this four-ring core structure.

Ganoderma (reishi) is the most studied, with over 495 lanostane-type triterpenoids identified (Galappaththi et al., 2022). Antrodia camphorata/cinnamomea contains zhankuic acids and antcins. Poria cocos (Fu Ling) contains pachymic acid and poricoic acids. Inonotus obliquus (Chaga) contains inotodiol and lanosterol itself. Several other medicinal mushroom species contain lanostane compounds in smaller amounts. The tetracyclic lanostane scaffold is a characteristic feature of several major medicinal mushroom genera.

Ganoderic acids are derived from lanosterol through a series of enzymatic modifications that oxidize, reduce, and otherwise modify the lanosterol backbone at specific positions. Lanosterol is the C30 tetracyclic precursor; ganoderic acids are the finished products after these modifications. Because all ganoderic acids start from lanosterol, they all retain the tetracyclic ring system (the lanostane scaffold) and differ only in what modifications have been made at various positions on the ring system and side chain.

Both are C30 triterpenoids but with different ring systems. Lanostane triterpenes have the tetracyclic ring system of lanosterol (with specific ring geometry and C-8,9 positioning). Ergostane triterpenes have the ergostane skeleton, which is the precursor to ergosterol (the fungal equivalent of cholesterol). Both are found in medicinal mushrooms; lanostane types are characteristic of Ganoderma, Antrodia, and Poria, while ergostane types include ergosterol and related compounds. The two subclasses have different intestinal absorption rates and biological activities.

No. Different Ganoderma species produce different lanostane compound profiles. Ganoderma lucidum (lingzhi/reishi) produces the most studied and most complex lanostane library, but other species like Ganoderma sinense, G. applanatum, and others produce both overlapping and distinct compound sets. Within any single species, the lanostane profile varies by cultivation conditions, geographic origin, and developmental stage. Standardized reishi extracts specify the ganoderic acid content because the raw profile is variable.

Sources & References

1. Source details for this reference are not yet available.
2. Source details for this reference are not yet available.
3. Source details for this reference are not yet available.
4. Source details for this reference are not yet available.
5. Source details for this reference are not yet available.
6. Source details for this reference are not yet available.
7. Source details for this reference are not yet available.
8. Source details for this reference are not yet available.